Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005

Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005

March 4, 2014

Patient Randomization and Dosing Underway in Allergic Conjunctivitis;

BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth

BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth

March 3, 2014

Appoints Andrew Hirsch as Chief Operating Officer and Jeff Hrkach as Chief Technology Officer

Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors

Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors

March 3, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company's board of directors.

Joule Appoints David Anton Chief Technology Officer

Joule Appoints David Anton Chief Technology Officer

February 28, 2014

Bedford, MA – February 28, 2014 –Joule today announced the appointment of David Anton as Executive Vice President and Chief Technology Officer. In this newly-created role, Dr. Anton will lead the transition of Joule’s CO2-to-fuels technology into a commercial reality. He brings nearly 30 years of relevant experience to the company, including prior technology and business leadership roles at DuPont and Codexis.

Joule Names Paul Snaith as New President and CEO

Joule Names Paul Snaith as New President and CEO

February 20, 2014

Bedford, MA – February 20, 2014 – Joule today announced the appointment of Paul Snaith as President and Chief Executive Officer, following his most recent post as Chief Operating Officer. He assumes the role from Noubar Afeyan, Executive Chairman and Founder of Joule, who had been serving as interim CEO.

Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease

Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease

February 18, 2014

Patient Randomization and Dosing Underway

Pronutria® Announces Launch of Two Clinical Trials

Pronutria® Announces Launch of Two Clinical Trials

February 13, 2014

Closes $12.25 Million in Series B Financing to Advance ProNutrein™ Product Candidates

Concert Pharmaceuticals Announces Pricing of Initial Public Offering

Concert Pharmaceuticals Announces Pricing of Initial Public Offering

February 13, 2014

LEXINGTON, Mass., Feb 13, 2014 (BUSINESS WIRE) -- Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments. The shares are scheduled to begin trading on the NASDAQ Global Market on February 13, 2014 under the ticker symbol "CNCE."

Tangent Medical Receives ISO 13485 Certification

Tangent Medical Receives ISO 13485 Certification

February 12, 2014

ANN ARBOR, MI – February 12, 2014 - Tangent Medical (www.tangentmedical.com), a manufacturer of IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, announced it has been awarded ISO 13485:2003 from the British Standards Institution (BSI). ISO 13485:2003 certification is the internationally recognized quality standard for medical devices and diagnostics.

Eleven Biotherapeutics Prices Initial Public Offering

Eleven Biotherapeutics Prices Initial Public Offering

February 6, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Eleven.